ストックスクリーナーアプリを入手
329.82
4.75%
-16.43
アフターアワーズ：
329.57
-0.25
-0.08%
前日終値:
$346.25
開ける：
$332.522
24時間の取引高:
3.80M
Relative Volume:
1.39
時価総額：
$178.10B
収益：
$36.74B
当期純損益:
$7.71B
株価収益率:
23.17
EPS:
14.2333
ネットキャッシュフロー:
$8.10B
1週間 パフォーマンス:
-4.28%
1か月 パフォーマンス:
-6.64%
6か月 パフォーマンス:
+10.52%
1年 パフォーマンス:
+16.22%
1日の値動き範囲:
$324.63
$337.00
1週間の範囲:
$324.63
$349.54
52週間の値動き範囲:
$261.43
$391.29
Amgen Inc Stock (AMGN) Company Profile
Compare AMGN vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
329.82 | 178.10B | 36.74B | 7.71B | 8.10B | 14.23 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-21 | 開始されました | Canaccord Genuity | Hold |
| 2026-03-10 | 開始されました | Jefferies | Hold |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-01-20 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-12-05 | アップグレード | Erste Group | Hold → Buy |
| 2025-11-24 | 再開されました | Truist | Hold |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-09-03 | 再開されました | Raymond James | Mkt Perform |
| 2025-05-20 | 再開されました | Guggenheim | Neutral |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 再開されました | BofA Securities | Underperform |
| 2024-11-15 | 開始されました | Wolfe Research | Peer Perform |
| 2024-11-14 | 開始されました | Citigroup | Neutral |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-14 | ダウングレード | Truist | Buy → Hold |
| 2024-09-27 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-08-07 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | アップグレード | Barclays | Underweight → Equal Weight |
| 2024-05-03 | アップグレード | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | 再開されました | Raymond James | Mkt Perform |
| 2024-02-07 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | アップグレード | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-11-02 | アップグレード | Truist | Hold → Buy |
| 2023-10-20 | 再開されました | JP Morgan | Neutral |
| 2023-10-17 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-10-11 | 再開されました | BofA Securities | Neutral |
| 2023-09-06 | 開始されました | HSBC Securities | Buy |
| 2023-04-24 | 繰り返されました | Oppenheimer | Outperform |
| 2023-03-13 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | 繰り返されました | Truist | Buy |
| 2022-11-18 | 開始されました | Credit Suisse | Underperform |
| 2022-10-31 | ダウングレード | Barclays | Equal Weight → Underweight |
| 2022-10-11 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-09 | 繰り返されました | Barclays | Equal Weight |
| 2022-02-09 | 繰り返されました | Jefferies | Buy |
| 2022-02-09 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2022-02-09 | 繰り返されました | Oppenheimer | Outperform |
| 2022-02-09 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-05 | ダウングレード | BofA Securities | Buy → Neutral |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Buy |
| 2021-11-19 | 開始されました | BMO Capital Markets | Market Perform |
| 2021-09-23 | ダウングレード | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | 開始されました | Daiwa Securities | Buy |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-10-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | アップグレード | Truist | Hold → Buy |
| 2020-10-09 | ダウングレード | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | ダウングレード | Truist | Buy → Hold |
| 2020-10-08 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | 再開されました | Guggenheim | Neutral |
| 2020-03-31 | 開始されました | Wolfe Research | Peer Perform |
| 2020-03-30 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-01-31 | ダウングレード | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-12-24 | 開始されました | Raymond James | Mkt Perform |
| 2019-12-17 | 再開されました | Morgan Stanley | Overweight |
| 2019-11-12 | 開始されました | SunTrust | Buy |
| 2019-11-05 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | 再開されました | BofA/Merrill | Neutral |
| 2019-08-19 | ダウングレード | Mizuho | Buy → Neutral |
| 2019-05-23 | アップグレード | Citigroup | Neutral → Buy |
すべてを表示
Amgen Inc (AMGN) 最新ニュース
Jennison Associates LLC Sells 91,343 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Margin Expansion In Q1 2026 Tests Cautious Growth Narratives - simplywall.st
Analysts Offer Insights on Healthcare Companies: Amgen (AMGN) and Icon (ICLR) - The Globe and Mail
Amgen Inc. Q1 2026 SEC 10-Q Report: Financial Statements, Defined Terms, and Product Overview 35384155 - Minichart
Amgen Earnings Call Highlights Growth Engines, Tax Risk - TipRanks
Assessing Amgen (AMGN) Valuation After Recent Share Price Weakness And Pipeline Expectations - Yahoo Finance
Amgen Inc (AMGN) Shares Fall 4.8% -- What GF Score of 93 Tells I - GuruFocus
Amgen Inc. stock underperforms Friday when compared to competitors - MSN
AMGN Maintains by Truist Securities -- Price Target Raised to $3 - GuruFocus
Amgen's Shannon Turley Inducted Into National Academy of Sciences - Amgen
Truist Financial Issues Positive Forecast for Amgen (NASDAQ:AMGN) Stock Price - MarketBeat
Amgen: The Quarter Where New Growth Engines Begin to Drown Out the Noise of Patent Expirations - marketscreener.com
Amgen (NASDAQ:AMGN) Shares Gap DownShould You Sell? - MarketBeat
Tranche Update on Amgen Inc.'s Equity Buyback Plan announced on April 21, 2011. - marketscreener.com
Amgen launches late-stage obesity trial in patients who switch from rival drugs - Endpoints News
Stock Market Today: Apple Earnings Power S&P 500, Nasdaq To Records; Trump Hits EU - Benzinga
IRS Seeks More Taxes From Amgen, Adding to $10.7 Billion Dispute - Bloomberg Law News
Amgen (NASDAQ:AMGN) Price Target Raised to $425.00 - MarketBeat
Amgen's Q1 Earnings Top Estimates, 16 Drugs Deliver Double-Digit Gains - The Globe and Mail
Apple leads Nasdaq higher at open, Amgen drags on Dow - Proactive financial news
Amgen Inc Stock (AMGN) Opened Down by 4.69% on May 1: A Full Analysis - TradingKey
Amgen 1st-qtr 2026 financials beat expectations - The Pharma Letter
Amgen Inc. (NASDAQ:AMGN) Q1 2026 Earnings Call Transcript - Insider Monkey
Nasdaq leads the pack as Apple impresses, Amgen drags on Dow - Yahoo! Finance Canada
Amgen Inc. $AMGN Shares Acquired by Sigma Planning Corp - MarketBeat
New York State Teachers Retirement System Sells 9,158 Shares of Amgen Inc. $AMGN - MarketBeat
BofA Securities raises Amgen stock price target on growth drivers By Investing.com - Investing.com Canada
Strategic Blueprint LLC Lowers Position in Amgen Inc. $AMGN - MarketBeat
Danske Bank A S Decreases Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Sold by Fifth Third Bancorp - MarketBeat
Amgen Inc (AMGN) Q1 2026 Earnings Call Highlights: Strong Produc - GuruFocus
Amgen Inc (AMGN) Q1 2026 Earnings Call Highlights: Strong Product Sales Growth Amidst Competitive Challenges - GuruFocus
AMGN Q1 Deep Dive: Growth Drivers Offset Patent Losses, Pipeline Progress in Focus - The Globe and Mail
Amgen (NASDAQ:AMGN) Issues Quarterly Earnings Results - MarketBeat
Amgen : C O R R E C T I O N Amgen/ - marketscreener.com
Amgen Doubles Down On Less Frequent MariTide Maintenance Dosing In Obesity - Citeline News & Insights
Amgen (AMGN) Q1 Earnings Exceed Expectations with Strong Revenue Growth - GuruFocus
Sixteen Amgen drugs posted double-digit sales growth in Q1 - Stock Titan
Amgen (NASDAQ: AMGN) posts Q1 2026 profit of $1.8B amid tax, product risks - Stock Titan
/C O R R E C T I O N -- Amgen/ - PR Newswire
Amgen (AMGN) Q1 2026 Earnings Transcript - AOL.com
Amgen (AMGN) Increases Revenue Projections for FY26 - GuruFocus
Amgen Q1 2026 slides: 16 brands fuel growth despite patent headwinds - Investing.com
Amgen Tops Estimates Despite Mixed Performance of Key Drugs - Bloomberg.com
Amgen Q1 Earnings Call Highlights - MarketBeat
Amgen (AMGN) Reports Strong Q1 Revenue Performance - GuruFocus
Amgen (AMGN) Adjusts Revenue Projections for FY26 Upwards - GuruFocus
Earnings call transcript: Amgen Q1 2026 beats expectations, raises guidance - Investing.com
Amgen sales rise 4% in first quarter, broadens weight-loss drug development - KFGO
Amgen (AMGN) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance
Earnings call transcript: Amgen Q1 2026 beats expectations, raises guidance By Investing.com - Investing.com Canada
Amgen Inc (AMGN) 財務データ
収益
当期純利益
現金流量
EPS
Amgen Inc (AMGN) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Option Exercise |
169.19 |
54,792 |
9,270,143 |
107,119 |
| Santos Esteban | EVP, Operations |
Feb 26 '26 |
Sale |
379.12 |
54,792 |
20,772,595 |
76,618 |
0.62%
1.39%
大文字化:
|
ボリューム (24 時間):